Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.10.5019

Predictive Role of GSTs on the Prognosis of Breast Cancer Patients with Neoadjuvant Chemotherapy  

Bai, Yun-Lu (Department of Ultrasound, the First Affiliated Hospital, Xinxiang Medical College)
Zhou, Bing (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College)
Jing, Xiao-Yue (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College)
Zhang, Bin (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College)
Huo, Xiao-Qing (Department of Radiotherapy, the First Affiliated Hospital, Xinxiang Medical College)
Ma, Chao (Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College)
He, Jian-Miao (Department of General Surgery, the 309th Hospital of Chinese People's Liberation Army)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.10, 2012 , pp. 5019-5022 More about this Journal
Abstract
Objective: To evaluate the predictive value of GST gene polymorphisms with regard to prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Methods: A total of 159 patients were included in our study between January 2005 and January 2007. All the patients were followed up until January 2012. Genotyping was based upon the duplex polymerase-chain-reaction with the PCR-CTPP method. Results: Patients with null GSTM1 and GSTP1 Val/Val genotypes had significantly had better response rates to chemotherapy when compared with non-null GSTM1 and GSTP1 Ile/Ile genotypes (OR=1.96 and OR=2.14, respectively). Patients with the GSTM1 null genotype had a longer average survival time and significantly lower risk of death than did those with non-null genotypes (HR=0.66). Similarly, those carrying the GSTP1 Val/Val genotype had 0.54-fold the risk of death of those with GSTP1 Ile/Ile (HR=0.54). Conclusion: A significant association was found between GSTM1 and GSTP1 gene polymorphisms and clinical outcomes in breast cancer cases.
Keywords
GSTM1; GSTT1; GSTP1; breast cancer; chemotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Funke S, Timofeeva M, Risch A, et al (2010). Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics, 11, 33-41.   DOI
2 International Agency for Research on Cancer (2008). Globocan 2008: Stomach Cancer incidence, Mortality and Prevalence Worldwide in 2008. IARC. http://globocan.iarc.fr/factsheets/cancers/liver.asp.
3 Lourenco GJ, Lorand-Metze I, Delamain MT, et al (2010). Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma, 51, 2215-21.   DOI
4 Mishra A, Chandra R, Mehrotra PK, et al (2011). Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today, 41, 471-6.   DOI
5 Mossallam GI, Abdel Hamid TM, Samra MA (2006). Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Canc Inst, 18, 264-73.
6 Nagle CM, Chenevix-Trench G, Spurdle AB, et al (2007). The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer, 43, 283-90.   DOI
7 Oliveira AL, Rodrigues FF, Santos RE, et al (2010). GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res, 9, 1045-53.   DOI
8 Ott K, Lordick F, Becker K, et al (2008). Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis, 23, 773-82.   DOI
9 Satta T, Isobe K, Yamauchi M, et al (1992). Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer, 69, 941-6.   DOI
10 Wang W, Xia CQ, Liu N, et al (2008). Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro. Cancer Chemother Pharmacol, 62, 117-22.   DOI
11 Wang L, Jiang Z, Sui M, et al (2009). The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer, 9, 226.   DOI   ScienceOn
12 Whelan RD, Waring CJ, Wolf CR, et al (1992). Overexpression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer, 52, 241-6.   DOI
13 Zheng J, Wurz GT, Cadman TB, et al (1997). Haloenol lactone: a new synergist of chemotherapy in vitro. Biochem Biophys Res Commun, 241, 13-7.   DOI
14 Arun BK, Granville LA, Yin G, et al (2010). Glutathione-stransferase- pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Investigation, 28, 554-9.   DOI
15 Ates NA, Tamer L, Ateş C, et al (2005). Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet, 43, 149-63.   DOI
16 Bafaloukos D (2005). Neo-adjuvant therapy in breast cancer. Ann Oncol, 16, 174-81.
17 Bosh TM, Meijerman I, Beijnen JH, et al (2006). Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet, 45, 253-85.   DOI
18 Franco RL, Schenka NG, Schenka AA, et al (2012). Glutathione S-transferase Pi expression in invasive breast cancer and its relation with the clinical outcome. J BUON, 17, 259-64.